Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Address: Amgen Ltd. Klimentská 46 110 02 Prague 1,Czech Republic
Tel: +420 221 773 500
Web: http://www.amgen.cz/
Amgen commenced operations in Central and Eastern Europe on 1 May 2004, when the first eight countries of the region became members of the EU. Since then, Amgen’s Central European activities have constantly expanded. Among the company’s focus markets in the region are the Czech Republic, Poland, Hungary, Slovakia and Romania. Amgen is also active in Lithuania, Latvia, Estonia, Slovenia, Bulgaria.Amgen entered the Czech market in May 2004.The company is headquartered in Prague, but its team covers the whole territory of the Republic. At present, the Czech branch has over 60 employees.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Teva Czech Republic & Slovakia GM Juan Carlos Conde describes how the Czech Republic hosts Teva’s third largest manufacturing site within Europe and the recent implementation of a more efficient…
Vojtěch Mészáros, Executive Director of Egis Praha, speaks about his background in the industry, his drive to promote biosimilar products, and how the company maneuvers around the growing price pressures…
Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment…
The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the…
The chairman of the committee on health and social policy of the Czech Senate names the role that health insurance companies inherit and the transparency of the healthcare system as…
The ’90s was an enthusiastic time. With the fall of communism in 1989 and the emergence of the free economy, the international pharmaceutical industry arrived in the Czech Republic…
Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology,…
Mr. Tichopad, can you please begin by introducing yourself and your company to our readers? My background is in bio-statistics. I am a biologist by education, and in the beginning…
Mr. Kužela, you have a very interesting background: from 1993 until 2011, you variously worked for the Staropramen beer factory and its parent organization, StarBev. You identify yourself as an…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Today, the Czech Republic is widely recognized as a major regional hub for clinical development. How would you compare the current environment to the realities of 1992, when CEPHA was…
Ms. Polekova, you established the Celgene affiliate in this country from scratch in 2008. When we spoke to Mr. Victor Ferkovich, your colleague in Russia, he commented on his own…
See our Cookie Privacy Policy Here
